Positive HCV clinical trial results could move ABBV to 51 - 52.....thought more clinic results were due this month. I'll sell some call options if it approaches 52. Unfortunately, tomorrow some of this nice move will be taken back and it will be in 49 land.
Because ENTA, ABBV and ABT are different companies. Doesn't make any difference how ENTA is doing or if Zacks has a good rating.....they are different companies.
I'm expecting a $1 or 2 move up in reaction to the HSP Investor Form scheduled for December 5th. Since the Form was announced by HSP I think they will have some good or optimistic news that will move the stock. I closed my calls and am looking to sell them again on any move to 41 - 42.
Second broker upgrade on ABBV in the last two days......really has a nice short term affect on the price. May have an additional upside price move after the Liver Disease meeting presentations over the weekend. Regardless, the upgrade today caused me to sell some covered call options at 52.50. Great price and you get the option premium......another 1.35 for me. May sell more calls on Friday or Monday....great opportunity to make a nice profit on future expectations. This is the time to realize some profit and take some money off the table.
I checked it out.....trades at $0.0078 on the OTC Pink Sheet. 52 week range 0.006 - 0.0571. 1, 6 and 12 month performance: -4.88%, -56.67% and -81.8%....what a loser.
Why is Abbv a great opportunity for a buy out? It has a lot of debt and only 1 major product, Humira. Abbv HCV product may or may not be successful...Gilead has the advantage for HCV treatment. Not sure why you think it's a great opportunity for a takeover.
"when I have a stock that falls 8% from its high I just sell and if rebounds, I can always buy it back." Sounds like you buy high and sell low.